Study: Orellanine for Patients with Advanced Kidney Cancer
Photo by Robina Weermeijer on Unsplash

Study: Orellanine for Patients with Advanced Kidney Cancer

According to an article recently published in Clinical Trials Arena, the Swedish pharmaceutical company Oncorena has recently initiated a Phase I/II trial for orellanine. This investigational treatment is intended for…

Continue Reading Study: Orellanine for Patients with Advanced Kidney Cancer
Study Finds Blocking Sphingolipids Counteracts Muscular Dystrophy in Mice Models
[Source: pixabay.com]

Study Finds Blocking Sphingolipids Counteracts Muscular Dystrophy in Mice Models

According to a recent article, a research team discovered that the inhibition of sphingolipid synthesis on mice models of Duchenne muscular dystrophy can counteract the certain symptoms of the disease.…

Continue Reading Study Finds Blocking Sphingolipids Counteracts Muscular Dystrophy in Mice Models

MHRA Approves Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in UK

According to a recent article, Revolo Biotherapeutics announced it has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for two Phase 2 clinical trials to analyze its…

Continue Reading MHRA Approves Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in UK

Doctors Receive Nobel Prize for Development in Renal Cell Carcinoma Treatment

Research by three doctors provided a basis for tyrosine kinase inhibitors (TKI) and offered advancements in treatment for renal cell carcinoma (RCC) patients. Two such TKIs, sunitinib and sorafenib, remain…

Continue Reading Doctors Receive Nobel Prize for Development in Renal Cell Carcinoma Treatment
It’s Congenital Heart Defect Awareness Week: Here’s What You Need to Know
source: pixabay.com

It’s Congenital Heart Defect Awareness Week: Here’s What You Need to Know

The week of February 7-14, 2022 is being recognized as Congenital Heart Defect Awareness Week, a time to help spread awareness about congenital heart defects. While individual heart defect conditions…

Continue Reading It’s Congenital Heart Defect Awareness Week: Here’s What You Need to Know
Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa
jniittymaa0 / Pixabay

Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa

People with epidermolysis bullosa (EB) often experience symptoms such as intense itching or severe pain. Unfortunately, these symptoms can be debilitating and may greatly affect overall quality-of-life. However, some burgeoning…

Continue Reading Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa

Studies of Head and Neck Cancer Show That Black Patients Have Worse Overall Survival Than Other People of Color

Researchers are aware that Black cancer patients experience worse outcomes than white cancer patients due to the differences in access to health care. According to a report in Cancer Network,…

Continue Reading Studies of Head and Neck Cancer Show That Black Patients Have Worse Overall Survival Than Other People of Color
Hypoparathyroidism Reduces Quality-of-Life, Study Shares
Parkinson's disease and dystonia are difficult diseases to live with for many reasons, not the least of which is that often drug therapy doesn't provide enough relief.

Hypoparathyroidism Reduces Quality-of-Life, Study Shares

It is no secret that certain conditions can sometimes be debilitating or make it harder to partake in day-to-day life. According to Hypoparathyroidism News, researchers recently sought to understand the…

Continue Reading Hypoparathyroidism Reduces Quality-of-Life, Study Shares
Adding Docetaxel to Cisplatin, 5-FU Improves Esophageal Cancer Overall Survival
source: pixabay.com

Adding Docetaxel to Cisplatin, 5-FU Improves Esophageal Cancer Overall Survival

From January 20th through the 22nd, 2022, researchers, specialists, and other stakeholders descended on the Gastrointestinal Cancers Symposium to discuss new and innovative research on gastrointestinal cancers. During the Symposium,…

Continue Reading Adding Docetaxel to Cisplatin, 5-FU Improves Esophageal Cancer Overall Survival